Louise Geddes1, Jenny Iversen1, Handan Wand1, Aryan Esmaeili2, Judith Tsui3, Margaret Hellard4, Gregory Dore1, Jason Grebely1, Paul Dietze4, Julie Bruneau5, Maria Prins6,7, Megan D Morris8, Naglaa H Shoukry5, Andrew R Lloyd1, Arthur Y Kim9, Georg Lauer9, Andrea L Cox10, Kimberly Page11, Lisa Maher1. 1. Kirby Institute, University of New South Wales Sydney, Australia. 2. Clinical Research Education, Icahn School of Medicine at Mount Sinai, New York. 3. University of Washington School of Medicine, Seattle. 4. Burnet Institute, Melbourne, Victoria, Australia. 5. Le Centre de recherche du Centre Hospitalier de l'Université de Montréal, Université de Montréal, Quebec, Canada. 6. Cluster Infectious Diseases, Public Health Service of Amsterdam, The Netherlands. 7. Amsterdam University Medical Center, University of Amsterdam, Department of Infectious Diseases, Amsterdam Infection and Immunity Institute, The Netherlands. 8. University of California, San Francisco. 9. Harvard Medical School, Boston, Massachusetts. 10. Department of Medicine, Johns Hopkins University, Baltimore, Maryland. 11. University of New Mexico Health Sciences Center, Albuquerque.
Abstract
BACKGROUND: While opioid agonist therapy (OAT) reduces the risk of hepatitis C virus (HCV) acquisition among people who inject drugs (PWID), protective effects may be attenuated in females. We used pooled data from an international collaboration of prospective cohorts to assess sex disparities in HCV incidence among PWID exposed to OAT. METHODS: Independent predictors of HCV infection were identified using Cox regression models with random effects after accounting for the clustering effect of study sites. Unadjusted and adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) are presented in sex-specific analyses. RESULTS: Among 701 participants exposed to OAT, HCV incidence was 16.5/100 person-years of observation (PYO) (95% CI, 13.1-20.7) in females and 7.6/100 PYO (95% CI, 6.0-9.5) in males (female:male adjusted HR [aHR], 1.80 [95% CI, 1.37-2.22]; P < .001). Factors associated with HCV acquisition among females exposed to OAT included nonwhite race (aHR, 1.79 [95% CI, 1.25-2.56]; P = .001), unstable housing (aHR, 4.00 [95% CI, 3.62-4.41]; P < .001), daily or more frequent injection (aHR, 1.45 [95% CI, 1.01-2.08]; P = .042), and receptive syringe sharing (aHR, 1.43 [95% CI, 1.33-1.53]; P < .001). CONCLUSIONS: Female PWID exposed to OAT are twice as likely as their male counterparts to acquire HCV. While there is a need for better understanding of sex differences in immune function and opioid pharmacokinetic and pharmacodynamic parameters, structural and behavioral interventions that target women are required to bolster the efficacy of OAT in preventing HCV transmission.
BACKGROUND: While opioid agonist therapy (OAT) reduces the risk of hepatitis C virus (HCV) acquisition among people who inject drugs (PWID), protective effects may be attenuated in females. We used pooled data from an international collaboration of prospective cohorts to assess sex disparities in HCV incidence among PWID exposed to OAT. METHODS: Independent predictors of HCV infection were identified using Cox regression models with random effects after accounting for the clustering effect of study sites. Unadjusted and adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) are presented in sex-specific analyses. RESULTS: Among 701 participants exposed to OAT, HCV incidence was 16.5/100 person-years of observation (PYO) (95% CI, 13.1-20.7) in females and 7.6/100 PYO (95% CI, 6.0-9.5) in males (female:male adjusted HR [aHR], 1.80 [95% CI, 1.37-2.22]; P < .001). Factors associated with HCV acquisition among females exposed to OAT included nonwhite race (aHR, 1.79 [95% CI, 1.25-2.56]; P = .001), unstable housing (aHR, 4.00 [95% CI, 3.62-4.41]; P < .001), daily or more frequent injection (aHR, 1.45 [95% CI, 1.01-2.08]; P = .042), and receptive syringe sharing (aHR, 1.43 [95% CI, 1.33-1.53]; P < .001). CONCLUSIONS: Female PWID exposed to OAT are twice as likely as their male counterparts to acquire HCV. While there is a need for better understanding of sex differences in immune function and opioid pharmacokinetic and pharmacodynamic parameters, structural and behavioral interventions that target women are required to bolster the efficacy of OAT in preventing HCV transmission.
Authors: Marjorie J Robertson; Richard A Clark; Edwin D Charlebois; Jacqueline Tulsky; Heather L Long; David R Bangsberg; Andrew R Moss Journal: Am J Public Health Date: 2004-07 Impact factor: 9.308
Authors: M Hickman; V Hope; T Brady; P Madden; S Jones; S Honor; G Holloway; F Ncube; J Parry Journal: J Viral Hepat Date: 2007-09 Impact factor: 3.728
Authors: Meghan D Morris; Stephen Shiboski; Julie Bruneau; Judith A Hahn; Margaret Hellard; Maria Prins; Andrea L Cox; Gregory Dore; Jason Grebely; Arthur Y Kim; Georg M Lauer; Andrew Lloyd; Thomas Rice; Naglaa Shoukry; Lisa Maher; Kimberly Page Journal: Clin Infect Dis Date: 2017-04-01 Impact factor: 9.079
Authors: Matthew J Akiyama; Daniel Lipsey; Moonseong Heo; Linda Agyemang; Brianna L Norton; Jennifer Hidalgo; Kiara Lora; Alain H Litwin Journal: Clin Infect Dis Date: 2020-06-10 Impact factor: 9.079